Lamzede (Velmanase Alfa)

Velmanase alfa is a recombinant form of human lysosomal alpha‑mannosidase. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes, where it restores the enzymatic activity needed to break down mannose‑rich oligosaccharides that build up in alpha‑mannosidosis.

The dosing regimen for Lamzede is individualized. The prescribing physician determines the appropriate dose, infusion rate, and frequency based on the patient’s weight, disease severity, and clinical response, following the product’s prescribing information.

Safety data for lamzede during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any potential risk to the fetus or infant, and the decision must be made by the treating healthcare professional.

To order Lamzede, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options, and the necessary import documentation.

Lamzede (velmanase alfa) is currently the only disease‑specific enzyme replacement therapy approved for alpha‑mannosidosis. Other management strategies are primarily supportive, addressing symptoms such as respiratory infections or hearing loss. Lamzede directly targets the underlying enzyme deficiency, offering a disease‑modifying approach.

Lamzede must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Proper cold‑chain handling is essential to maintain product stability until administration.

Lamzede is supplied as a sterile solution for injection and is administered by intravenous infusion. The infusion is performed under medical supervision in a clinical setting, with monitoring for infusion‑related reactions during and after the administration.

Serious adverse events associated with Lamzede include anaphylaxis, severe hypersensitivity reactions, significant elevations in liver enzymes, renal impairment, and rare thrombotic or embolic events. Patients should be closely monitored during and after infusion for any signs of these reactions.

Lamzede should not be used in patients with known hypersensitivity to velmanase alfa or any excipients in the formulation. Additionally, individuals for whom the risk of severe immune or allergic reactions outweighs the potential therapeutic benefit should be excluded from treatment.